# Patient-Trial Match Report

*Generated: 2026-01-05 06:55:18*

## Patient Profile

- **Age**: 58
- **Sex**: Female
- **Cancer Type**: NSCLC
- **Biomarkers**: KRAS G12C

**Clinical Description**:
> 58-year-old female with metastatic NSCLC (adenocarcinoma), KRAS G12C positive. Treated brain metastases with stereotactic radiosurgery (SRS) 6 months ago - currently radiographically stable and off steroids x3 months. Failed first-line docetaxel/ramucirumab (PD-L1 negative). Now with progressive lung and adrenal lesions. Performance status has declined slightly over past month. Cardiac history: well-controlled hypertension on lisinopril. Never smoker. Labs: mild anemia (Hgb 10.2), otherwise WNL.

- **Location Preference**: United States, Canada

## Search Summary

- **Search terms used**: 12
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 10
- **LLM scored**: 90

## ðŸŸ¢ HIGH Likelihood (21 trials)

### [NCT04613596](https://clinicaltrials.gov/study/NCT04613596)

**A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation**

- **Sponsor**: Mirati Therapeutics Inc.
- **Phase**: Phase 2/Phase 3
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of metastatic NSCLC with KRAS G12C mutation
- Brain metastases are stable and do not require immediate local therapy
- ECOG status of 1

**? Uncertainties:**
- No details provided about organ function or lab results other than mild anemia.

**Assessment:**
> The patient's cancer type, NSCLC, matches the trial's focus. The patient has KRAS G12C mutation and falls within the required eligibility regarding prior therapies and current health status. The minor uncertainty relates to organ function which isn't specified. Overall, the patient likely qualifies.

---

### [NCT06162221](https://clinicaltrials.gov/study/NCT06162221)

**A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient is 58 years old and meets the age criteria (â‰¥ 18 years)
- ECOG performance status is 1
- Has pathologically documented, metastatic KRAS G12C-mutated NSCLC
- Received prior standard therapy (docetaxel/ramucirumab) appropriate for tumor type and stage

**? Uncertainties:**
- Organ function is not explicitly detailed in the profile
- Specific lab values are not provided for adequate organ function assessment

**Assessment:**
> The patient's cancer type matches the trial's focus on KRAS G12C-mutated NSCLC. The patient has prior treatment, which aligns with the trial criteria for previously treated patients. The only uncertainties pertain to specific organ function details, which are not provided.

---

### [NCT07227025](https://clinicaltrials.gov/study/NCT07227025)

**A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer**

- **Sponsor**: Janssen Research & Development, LLC
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically confirmed metastatic NSCLC (adenocarcinoma)
- KRAS G12C mutation
- ECOG performance status of 1
- Prior therapies include platinum-based chemotherapy (docetaxel and ramucirumab)

**? Uncertainties:**
- Presence of at least 1 measurable lesion that has not been previously irradiated
- Details regarding organ function labs

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) aligns with the trial's focus. The patient is not treatment-naive, having progressed after prior therapies aligned with trial requirements for previously treated patients. Although there are some uncertainties regarding measurable lesions and organ function, these are minor and do not affect the primary eligibility criteria.

---

### [NCT05815173](https://clinicaltrials.gov/study/NCT05815173)

**Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: NYU Langone Health
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 58 (>= 18)
- ECOG status: 1 (acceptable)
- Histologically confirmed diagnosis of NSCLC (non-squamous)
- Metastatic NSCLC (not candidates for curative surgery or radiation)
- Documentation of KRAS G12C mutation present
- Progression of disease after prior treatment with anti-PD-L1 (docetaxel/ramucirumab)
- Stable brain metastases (treated >6 months ago, off steroids for >3 months)
- Prior therapies completed (docetaxel, ramucirumab)
- Location: United States (location matches trial eligibility)

**? Uncertainties:**
- Absolute neutrophil count
- Platelet count
- Hemoglobin (must be >= 8 g/dL, patient at 10.2 g/dL)
- Albumin
- Lymphocyte count
- Serum bilirubin
- AST and ALT levels
- Renal clearance (eGFR)
- No mention of pregnancy status (if applicable)
- No active infection or history of other conditions impacting eligibility

**Assessment:**
> Patient has a confirmed diagnosis of NSCLC with the specific KRAS G12C mutation which matches the trial's indication. The patient has previously been treated, but this trial is designed for previously treated patients, thus aligning with treatment line eligibility. Additional criteria regarding laboratory values and health conditions require verification but do not conflict with clear eligibility.

---

### [NCT06225804](https://clinicaltrials.gov/study/NCT06225804)

**A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer**

- **Sponsor**: Abbisko Therapeutics Co, Ltd
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic NSCLC (adenocarcinoma)
- Patient has ECOG status of 1
- Patient is aged 58
- Patient has stable brain metastases
- Patient has documented progression on previous therapies

**? Uncertainties:**
- Adequate organ function and bone marrow function - specific lab results not provided
- Electrolyte levels - specific lab results not provided

**Assessment:**
> The patient's cancer type (metastatic NSCLC) matches the trial's focus. She is a previously treated patient, which fits the trial's inclusion criteria. While there are uncertainties regarding specific organ function lab results, the overall profile suggests she likely meets the eligibility criteria.

---

### [NCT06249282](https://clinicaltrials.gov/study/NCT06249282)

**A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer**

- **Sponsor**: City of Hope Medical Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 58 (â‰¥ 18 years)
- ECOG status: 1 (â‰¤ 2)
- Cancer type: NSCLC (histologically confirmed and metastatic)
- Biomarker: KRAS G12C positive (required mutation)
- Stable brain metastases (physician determined immediate CNS treatment not required)
- Hemoglobin: 10.2 (â‰¥ 9 g/dL requirement met)
- Prior therapies: Failed prior KRAS inhibitor (docetaxel/ramucirumab considered first-line therapy)

**? Uncertainties:**
- Absolute neutrophil count (ANC)
- Platelets
- Total bilirubin
- AST
- ALT
- Creatinine clearance/GFR

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's indications, and she has the required KRAS G12C mutation. She has a favorable ECOG status and is older than the minimum age requirement. Although some organ function assessments are uncertain, all critical eligibility criteria are satisfied, leading to a high likelihood of match.

---

### [NCT06343402](https://clinicaltrials.gov/study/NCT06343402)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Histologically documented metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation
- ECOG performance status 1
- Stable brain metastases treated with SRS

**? Uncertainties:**
- Exact status of measurable disease by RECIST v1.1
- Specific results of organ function labs beyond mild anemia

**Assessment:**
> The patient's cancer type matches exactly with the trial's indication, and she has the required biomarker (KRAS G12C). While she is not treatment-naive due to prior therapies, the trial is not explicitly limited to treatment-naive patients, allowing for a strong likelihood of eligibility. The only uncertainties are related to measurable disease status and complete organ function, but overall criteria are met.

---

### [NCT05410145](https://clinicaltrials.gov/study/NCT05410145)

**A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation**

- **Sponsor**: D3 Bio (Wuxi) Co., Ltd
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has a confirmed metastatic NSCLC which is the target disease of the trial.
- Patient has a documented KRAS G12C mutation identified.
- ECOG performance status is 1.
- Clinical details indicate measurable disease with progressive lung and adrenal lesions.

**? Uncertainties:**
- Organ function labs are not provided.
- Prior treatment washout period and definition not stated.

**Assessment:**
> The patient has a confirmed diagnosis of metastatic NSCLC, which aligns with the trial's focus on KRAS G12C mutant tumors. The patient has also provided the necessary biomarker status and meets the ECOG performance status requirement. Some uncertainties exist regarding organ function and prior treatment washout, but they do not significantly affect overall eligibility.

---

### [NCT06244771](https://clinicaltrials.gov/study/NCT06244771)

**An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors**

- **Sponsor**: Frontier Medicines Corporation
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed metastatic NSCLC with KRAS G12C mutation.
- ECOG performance status is 1.
- Patient has received and progressed through prior standard therapy.

**? Uncertainties:**
- Adequate hematological, renal, and hepatic function is not explicitly documented.
- There is no mention of other interventional studies while receiving study drug.

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's focus on KRAS G12C mutations, and the patient has a performance status of 1 and has progressed after standard therapy. While there are uncertainties about organ function and concurrent studies, these are not critical for exclusion.

---

### [NCT06973564](https://clinicaltrials.gov/study/NCT06973564)

**A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration**

- **Sponsor**: Jacobio Pharmaceuticals Co., Ltd.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic solid tumor (NSCLC)
- Patient has KRAS alteration (G12C)
- ECOG status is 1
- Patient has a life expectancy â‰¥3 months

**? Uncertainties:**
- Archived tumor sample availability is not confirmed
- Patient has not confirmed the presence of a measurable lesion

**Assessment:**
> The patient has a confirmed diagnosis of metastatic NSCLC, which aligns with the trial's focus on advanced solid tumors with KRAS alterations. The patient is 58 years old, with an ECOG performance status of 1, and has a life expectancy greater than 3 months, meeting key eligibility criteria. While there are uncertainties regarding the availability of an archived tumor sample and confirmation of a measurable lesion, these do not affect the overall match likelihood significantly.

---

### [NCT07209111](https://clinicaltrials.gov/study/NCT07209111)

**A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)**

- **Sponsor**: Merck Sharp & Dohme LLC
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosed with metastatic NSCLC
- Has KRAS G12C mutation
- ECOG status of 1
- Has progressed on prior standard of care systemic treatment

**Assessment:**
> The patient has metastatic NSCLC, which matches the trial's indicated target cancer type. The patient has the necessary KRAS G12C mutation and has progressed after standard treatment, aligning with the trial's requirement for previously treated patients. No conflicts or uncertainties were identified.

---

### [NCT00068003](https://clinicaltrials.gov/study/NCT00068003)

**Cell Harvest and Preparation for Surgery Branch Treatment Protocols**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Enrolling by invitation
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type: Non-Small Cell Lung Cancer
- ECOG status: 1
- Age: 58

**? Uncertainties:**
- Specific lab values (e.g., serology for HIV, hepatitis B and C) are not provided.

**Assessment:**
> The patient's cancer type of Non-Small Cell Lung Cancer matches the trial's studied condition. Furthermore, the patient's ECOG status is within acceptable limits (1) and they are of eligible age (58). There are no explicit conflicts, and the main uncertainty relates to serology results that are not specified.

---

### [NCT06026410](https://clinicaltrials.gov/study/NCT06026410)

**Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors**

- **Sponsor**: Kura Oncology, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 58
- Sex: female
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: docetaxel, ramucirumab
- Brain metastases: stable
- Treatment line: progressive lung and adrenal lesions indicating previously treated

**? Uncertainties:**
- Specifics regarding organ function labs are not provided.

**Assessment:**
> The patient's cancer type (advanced NSCLC with KRAS G12C mutation) aligns with the trial's focus on NSCLC. The patient has received prior systemic therapies, qualifying them for a trial that studies previously treated patients. While lab results regarding organ function are unclear, the patient's other critical criteria are met.

---

### [NCT06128551](https://clinicaltrials.gov/study/NCT06128551)

**Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type: NSCLC (adenocarcinoma)
- Biomarker: KRAS G12C positive
- ECOG status: 1
- Stable brain metastases treated 6 months ago

**? Uncertainties:**
- Adequate organ function is not explicitly stated in the labs
- Only mild anemia is mentioned; other organ functions are unclear

**Assessment:**
> The patient's cancer type (NSCLC) matches the trial's conditions, and they have the required KRAS G12C mutation. They are previously treated, which aligns with the trial's eligibility for previously treated patients. ECOG status is acceptable, and their brain metastases have been treated and are stable. Although there are uncertainties about organ function, the patient meets critical eligibility criteria.

---

### [NCT06403436](https://clinicaltrials.gov/study/NCT06403436)

**A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors**

- **Sponsor**: TOLREMO therapeutics AG
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 58
- Sex: female
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: docetaxel, ramucirumab, SRS brain
- Brain metastases: stable
- Adequate hematological function: Hemoglobin 10.2 (greater than 9 g/dL)
- Life expectancy of > 3 months (based on clinical details)

**? Uncertainties:**
- Hematological function (absolute neutrophil count and platelet count not provided)
- Hepatic function (bilirubin, AST, and ALT levels not provided)
- Renal function (creatinine clearance not provided)
- Coagulation laboratory assessments (PT/PTT/INR levels not provided)

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) matches the trial's focus on advanced solid tumors, and the patient has prior treatments which align with the inclusion criteria of being refractory to standard treatment. Although some lab results are missing, the key inclusion criteria are met.

---

### [NCT06607185](https://clinicaltrials.gov/study/NCT06607185)

**A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has NSCLC, which is a condition studied in the trial.
- Patient has KRAS G12C mutation, which is a required biomarker.
- Patient has ECOG status of 1, which is within eligible range.
- Patient has stable brain metastases treated with SRS.
- Patient did not have any unresolved toxicities greater than Grade 1 from prior treatments.
- Patient is able to swallow tablets as indicated.

**Assessment:**
> The patient's NSCLC diagnosis matches the trial condition, and she has the required KRAS G12C biomarker. She falls within the acceptable ECOG performance status and presents with stable brain metastases after treatment. All other eligibility criteria from the trial are met without any noted conflicts or uncertainties.

---

### [NCT06917079](https://clinicaltrials.gov/study/NCT06917079)

**A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers**

- **Sponsor**: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type is NSCLC, which matches the trial conditions for KRAS mutant cancers.
- Patient has KRAS G12C mutation, which is included in the trial's eligibility criteria.
- ECOG performance status is 1, which is acceptable according to trial criteria.
- Patient has measurable disease as indicated by progressive lung and adrenal lesions.

**Assessment:**
> The patient's cancer type (NSCLC) aligns with the trial conditions, and the patient has the required KRAS G12C mutation. The ECOG status and indication of measurable disease also support eligibility. There are no significant conflicts or uncertainties that would exclude the patient.

---

### [NCT07094204](https://clinicaltrials.gov/study/NCT07094204)

**A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications**

- **Sponsor**: Astellas Pharma Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed metastatic NSCLC.
- Patient has KRAS G12C mutation.
- Patient has an ECOG status of 1.
- Patient has stable brain metastases.
- Patient has received prior standard therapy and is not receiving any continuing therapy.

**? Uncertainties:**
- Patient's organ function labs are not provided explicitly.

**Assessment:**
> The patient's cancer type (NSCLC), treatment history (prior therapies), and biomarker (KRAS G12C) match the trial's criteria. The ECOG status is within the acceptable range. Organ function labs are not specified but do not conflict with other criteria. Therefore, the patient is likely eligible.

---

### [NCT05786924](https://clinicaltrials.gov/study/NCT05786924)

**A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies**

- **Sponsor**: Institut de Recherches Internationales Servier
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Age: 58
- Sex: female
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Prior therapies: docetaxel, ramucirumab, SRS brain
- Brain metastases: stable

**? Uncertainties:**
- Adequate bone marrow and organ function is unclear.
- Life expectancy of â‰¥ 12 weeks is based on investigator's opinion.
- Lab results for organ function are not provided.

**Assessment:**
> The patient's cancer type (NSCLC) and biomarker (KRAS G12C) align with the trial's conditions. The patient is previously treated, which matches the trial requirements for Part 2 (Dose Optimization and Expansion). However, there are uncertainties regarding organ function and the life expectancy assessment, leading to a medium confidence level.

---

### [NCT06720987](https://clinicaltrials.gov/study/NCT06720987)

**A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations**

- **Sponsor**: Kumquat Biosciences Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Histologically confirmed diagnosis of metastatic NSCLC (adenocarcinoma) with KRAS G12C mutation
- Unresectable metastatic disease
- ECOG status of 1
- Stable brain metastases post-SRS treatment
- No available treatment with curative intent
- Mild anemia but otherwise within normal limits (WNL) for organ function

**âœ— Potential Conflicts:**
- Patient has prior therapies (docetaxel, ramucirumab) which may imply previous treatment status

**? Uncertainties:**
- Specific organ function criteria not provided
- Details on whether the mild anemia affects eligibility are unclear

**Assessment:**
> The patient has a confirmed diagnosis of NSCLC with the required KRAS G12C mutation, meeting the disease criteria for the trial. However, the patient has received prior treatments, which introduces uncertainty regarding the treatment line eligibility within the context of the trial's requirements.

---

### [NCT06881784](https://clinicaltrials.gov/study/NCT06881784)

**RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC**

- **Sponsor**: Revolution Medicines, Inc.
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- Female patient with pathologically confirmed NSCLC (adenocarcinoma)
- ECOG status of 1
- Documented KRAS G12C mutation
- Prior therapies include docetaxel and ramucirumab, which qualifies as previously treated

**âœ— Potential Conflicts:**
- Patient has received prior therapy with docetaxel, which is an exclusion criteria

**? Uncertainties:**
- Adequate organ function details are not provided in the lab results

**Assessment:**
> The patient has NSCLC which matches the disease criteria, and her ECOG status is within the acceptable range. However, she has received prior therapy with docetaxel, which excludes her from this trial.

---

## ðŸŸ¡ MEDIUM Likelihood (6 trials)

### [NCT05074810](https://clinicaltrials.gov/study/NCT05074810)

**A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)**

- **Sponsor**: Verastem, Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has metastatic NSCLC
- Patient has KRAS G12C mutation
- ECOG status is 1
- Patient has received prior systemic therapy

**? Uncertainties:**
- Measurable disease according to RECIST 1.1 is not confirmed
- Organ function assessment is not provided

**Assessment:**
> The patient's cancer type (NSCLC) and biomarker (KRAS G12C) align with the trial's focus. The patient has received prior systemic therapy, which fits the eligibility criteria for previously treated patients. However, there are uncertainties regarding the confirmation of measurable disease, which is necessary for full eligibility. Therefore, while the patient is likely eligible, verification of additional criteria is needed.

---

### [NCT04956640](https://clinicaltrials.gov/study/NCT04956640)

**A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has KRAS G12C mutation
- ECOG status is 1
- Patient has a confirmed diagnosis of metastatic NSCLC

**âœ— Potential Conflicts:**
- Patient is previously treated with docetaxel and ramucirumab, trial may require treatment-naive patients

**? Uncertainties:**
- Adequate organ function labs are not provided
- No specific mention of whether the patient can swallow capsules/tablets

**Assessment:**
> The patient has a qualifying cancer type of NSCLC and meets the biomarker requirement for KRAS G12C. However, the patient has prior treatments which may conflict with the trial's requirement for treatment-naive patients, leading to some uncertainty regarding eligibility.

---

### [NCT06814496](https://clinicaltrials.gov/study/NCT06814496)

**RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3**

- **Sponsor**: University of Arizona
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient is 58 years old, over the minimum age requirement of 18.
- ECOG status is 1, which is within the acceptable range (0-2).
- Patient has NSCLC, which is included in the study conditions.
- Patient has progressive disease after prior therapies, matching the requirement for having progressed after at least one line of therapy.

**âœ— Potential Conflicts:**
- Biomarker for DLL3 positivity is not available; studies may exclude if eligibility for the cohort requires DLL3 positivity.
- Patient has stable brain metastases; however, there is a specific requirement related to brain metastases being asymptomatic and meeting other criteria.

**? Uncertainties:**
- Required lab results for adequate organ function are not provided, particularly hemoglobin (should be >9 g/dL) and other blood parameters.
- Details regarding the presence of measurable lesions as defined by RECIST criteria are not specified.
- Patient's history regarding any systemic infection or sites amenable to radiation therapy requires further verification.

**Assessment:**
> The patient has a matching cancer type and has previously been treated, meeting several inclusion criteria. However, there are uncertainties regarding several eligibility aspects, particularly concerning biomarker requirements and organ function labs.

---

### [NCT02178163](https://clinicaltrials.gov/study/NCT02178163)

**A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.**

- **Sponsor**: Barbara Ann Karmanos Cancer Institute
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 60%

**âœ“ Supporting Factors:**
- Patient has metastatic Non-Small Cell Lung Cancer (NSCLC).
- Zubrod performance status is 1.
- Patient has KRAS G12C mutation.
- Patient has prior treatments documented (docetaxel and ramucirumab).

**âœ— Potential Conflicts:**
- Patient does not have PD-L1 TPS â‰¥50% as it is <1%.
- Patient has had prior systemic therapy, which may conflict with first-line criteria.

**? Uncertainties:**
- Absolute neutrophil count is unknown.
- Platelet count is unknown.
- Serum creatinine level is unknown.
- Serum bilirubin level is unknown.
- Transaminase levels are unknown.

**Assessment:**
> The patient's cancer type is appropriate for the trial, but there is uncertainty regarding several key laboratory values, and the patient's treatment history raises potential conflicts with eligibility. These factors lower the confidence but suggest that further verification may yield eligibility.

---

### [NCT06130254](https://clinicaltrials.gov/study/NCT06130254)

**Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 55%

**âœ“ Supporting Factors:**
- Patient has NSCLC with KRAS G12C mutation.
- Patient is 58 years old.
- ECOG status is 1.
- Patient has stable brain metastases that were treated.

**âœ— Potential Conflicts:**
- Trial requires both KRAS G12C and KEAP1 co-mutations for NSCLC, patient only has KRAS G12C.

**? Uncertainties:**
- Laboratory values for organ function (e.g., absolute neutrophil count, platelet count, hemoglobin, total bilirubin, AST/ALT, creatinine clearance) are not provided, which are needed for eligibility assessment.

**Assessment:**
> The patient's cancer type (NSCLC with KRAS G12C mutation) aligns with the trial, but the absence of a KEAP1 co-mutation conflicts with trial eligibility. Additionally, lacking specific lab results creates uncertainty regarding other eligibility criteria.

---

### [NCT03948100](https://clinicaltrials.gov/study/NCT03948100)

**Dyadic Behavioral Interventions to Manage Physical Performance, Symptoms and Quality of Life for Patient Undergoing Radiotherapy and Their Family Caregivers**

- **Sponsor**: M.D. Anderson Cancer Center
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 50%

**âœ“ Supporting Factors:**
- Patient has non-small cell lung cancer (NSCLC)
- ECOG status is 1
- Patient has a family caregiver

**âœ— Potential Conflicts:**
- Patient has stable brain metastases which may conflict with exclusion criteria for central nervous system involvement
- Patient is not treatment-naive as she has received prior systemic therapy (docetaxel and ramucirumab)

**? Uncertainties:**
- Patient's ability to read, write, and speak English is not confirmed
- Patient's lab results related to organ function except mild anemia are not provided
- Information about imminent thoracic radiotherapy is not provided

**Assessment:**
> The patient has a diagnosis of NSCLC which aligns with the trial's condition studied. However, there is a conflict due to stable brain metastases and prior therapy, which raises uncertainties about eligibility for the specific trial requirements.

---

## ðŸŸ  LOW Likelihood (5 trials)

### [NCT05853575](https://clinicaltrials.gov/study/NCT05853575)

**A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation**

- **Sponsor**: Mirati Therapeutics Inc.
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Age: 58
- Sex: female
- Cancer type: NSCLC
- Biomarkers: KRAS G12C
- ECOG status: 1
- Brain metastases: stable

**âœ— Potential Conflicts:**
- Failed first-line treatment with docetaxel and ramucirumab; trial requires previous treatment with cisplatin or carboplatin and an immune checkpoint inhibitor.
- Patient has stable brain metastases but recent treatment does not meet criteria due to inclusion criteria limitations on untreated brain lesions.

**? Uncertainties:**
- Labs: need more information on organ function besides mild anemia.

**Assessment:**
> While the patient's cancer type and biomarker are aligned with the trial's focus on NSCLC and KRAS G12C mutation, the patient's prior therapies do not meet the trial's treatment requirements. Furthermore, although the brain metastases are stable, the exclusion criteria may still be applicable based on the patient's treatment history and current condition. Therefore, the patient is likely excluded.

---

### [NCT06890598](https://clinicaltrials.gov/study/NCT06890598)

**A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02**

- **Sponsor**: Eli Lilly and Company
- **Phase**: Phase 3
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Patient has histological confirmation of NSCLC.
- Patient has KRAS G12C mutation.
- Patient has ECOG performance status of 1.

**âœ— Potential Conflicts:**
- Patient is classified as metastatic NSCLC with progressive disease, whereas trial eligibility specifically requires clinical Stage II-IIIB treated with presurgical chemoimmunotherapy or clinical Stage III unresectable NSCLC without progression on concurrent platinum-based chemoradiotherapy.
- Patient's PD-L1 expression is <1%, which may not meet the threshold for trial inclusion depending on specific treatment arms.

**? Uncertainties:**
- Adequacy of laboratory parameters is not explicitly stated in the profile.

**Assessment:**
> The cancer type matches, but the patient's disease status with progressive NSCLC does not align with the trial's eligibility criteria for treatment stages. Additionally, the low PD-L1 TPS may be a restricting factor. Therefore, the patient is likely excluded.

---

### [NCT04852588](https://clinicaltrials.gov/study/NCT04852588)

**Endoscopic Nodal Staging in Oligometastatic Non-small Cell Lung Cancer (NSCLC) Being Treated With Stereotactic Ablative Radiotherapy (ENDO-SABR)**

- **Sponsor**: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Age is 58, which is above the minimum age of 18
- ECOG status is 1, which is acceptable

**âœ— Potential Conflicts:**
- Patient has metastatic NSCLC with progressive disease, while the trial requires oligometastatic NSCLC
- Patient has previously received systemic therapy (docetaxel/ramucirumab), while the trial likely expects treatment-naive or first-line patients

**? Uncertainties:**
- Organ function labs (e.g., liver, kidney function) are not provided
- Whether patient has been staged within 3 months prior to registration is not confirmed
- No information on contraindications for EBUS/EUS or ability to provide consent for these procedures

**Assessment:**
> The patient has metastatic NSCLC, which does not match the trial's requirement for oligometastatic disease. Additionally, the patient has received prior systemic therapy, which conflicts with the likely treatment-naive population the trial is targeting.

---

### [NCT06545331](https://clinicaltrials.gov/study/NCT06545331)

**A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors**

- **Sponsor**: Exelixis
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Age is 58, which is above the minimum age of 18
- ECOG performance status is 1
- Cancer type is NSCLC, which is included in the trial conditions

**âœ— Potential Conflicts:**
- Patient is previously treated with docetaxel and ramucirumab, while the trial primarily focuses on previously untreated patients
- PD-L1 TPS is <1%, which does not meet requirements for PD-L1 expression

**? Uncertainties:**
- Adequate organ and marrow function is not confirmed
- Whether the patient meets the sufficient stability criteria post brain metastases treatment

**Assessment:**
> The patient has NSCLC, which aligns with the trial's focus. However, they have previously received systemic treatment, which likely disqualifies them from a trial suggesting first-line therapy, and their PD-L1 expression level is below the acceptable threshold, leading to a significant likelihood of exclusion.

---

### [NCT05076760](https://clinicaltrials.gov/study/NCT05076760)

**Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors**

- **Sponsor**: Memgen, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- ECOG performance status: 1
- Cancer type: NSCLC
- Biomarker: KRAS G12C

**âœ— Potential Conflicts:**
- Patient has not progressed on anti-PD-1/PD-L1 therapy, failing Part 1B and 1C eligibility.
- Patient has not received first-line PD-1/PD-L1 therapy; therefore, does not meet treatment line for Parts 1B and 1C.

**? Uncertainties:**
- Organ function lab results are not provided, particularly for creatinine clearance, bilirubin, AST, and ALT.

**Assessment:**
> The patient's cancer type matches NSCLC, but she has not received anti-PD-1/PD-L1 therapy, which is required for the trial's eligibility, leading to a conflict in the treatment line assessment.

---

## Excluded (68 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT04130516](https://clinicaltrials.gov/study/NCT04130516) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04300556](https://clinicaltrials.gov/study/NCT04300556) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04589845](https://clinicaltrials.gov/study/NCT04589845) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05419375](https://clinicaltrials.gov/study/NCT05419375) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05638295](https://clinicaltrials.gov/study/NCT05638295) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05892068](https://clinicaltrials.gov/study/NCT05892068) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04929223](https://clinicaltrials.gov/study/NCT04929223) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05720117](https://clinicaltrials.gov/study/NCT05720117) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06804824](https://clinicaltrials.gov/study/NCT06804824) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06807619](https://clinicaltrials.gov/study/NCT06807619) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT04302025](https://clinicaltrials.gov/study/NCT04302025) | Genentech, Inc. | Patient has prior therapies (docetaxel, ramucirumab) and the trial requires treatment-naive patients. |
| [NCT05118854](https://clinicaltrials.gov/study/NCT05118854) | M.D. Anderson Cancer | Patient is not treatment-naive as she has previously received docetaxel and ramucirumab, while the trial is for treatment-naive patients. |
| [NCT05609578](https://clinicaltrials.gov/study/NCT05609578) | Mirati Therapeutics  | Patient has failed prior systemic therapies (docetaxel, ramucirumab), while the trial requires treatment-naive patients. |
| [NCT05789082](https://clinicaltrials.gov/study/NCT05789082) | Hoffmann-La Roche | Trial requires treatment-naive patients and the patient has prior systemic therapy (docetaxel, ramucirumab). |
| [NCT05845671](https://clinicaltrials.gov/study/NCT05845671) | University of Colora | Patient has NSCLC with KRAS G12C mutation, but the trial only includes patients with ALK, ROS1, or RET gene fusions. |
| [NCT05920356](https://clinicaltrials.gov/study/NCT05920356) | Amgen | Patient has received prior systemic therapy (docetaxel/ramucirumab), while the study requires no history of systemic anticancer therapy in metastatic settings. |
| [NCT06312137](https://clinicaltrials.gov/study/NCT06312137) | Merck Sharp & Dohme  | Patient has already received prior systemic therapies (docetaxel and ramucirumab), while this trial appears to require treatment-naive patients. |
| [NCT06345729](https://clinicaltrials.gov/study/NCT06345729) | Merck Sharp & Dohme  | Patient has failed prior systemic anticancer therapy (docetaxel/ramucirumab) while the trial requires treatment-naive patients. |
| [NCT06385262](https://clinicaltrials.gov/study/NCT06385262) | Duke University | Patient has prior therapies (docetaxel, ramucirumab) while trial excludes any prior chemotherapy for current lung cancer diagnosis. |
| [NCT06561386](https://clinicaltrials.gov/study/NCT06561386) | Bristol-Myers Squibb | Patient has prior systemic therapy (docetaxel, ramucirumab), while the trial requires treatment-naive patients. |
| [NCT06582771](https://clinicaltrials.gov/study/NCT06582771) | Memorial Sloan Kette | Patient has received prior systemic therapy (docetaxel/ramucirumab). Trial requires no prior therapy in the advanced setting. |
| [NCT06793215](https://clinicaltrials.gov/study/NCT06793215) | Hoffmann-La Roche | Patient has prior systemic treatment (docetaxel and ramucirumab), whereas trial specifies no prior systemic treatment for advanced or metastatic NSCLC. |
| [NCT06875310](https://clinicaltrials.gov/study/NCT06875310) | Mirati Therapeutics  | Patient has prior systemic anti-cancer therapy (docetaxel, ramucirumab) for advanced disease, whereas trial is for treatment-naive patients |
| [NCT07155187](https://clinicaltrials.gov/study/NCT07155187) | AbbVie | Patient has NSCLC with KRAS G12C mutation, but trial requires EGFR mutation (Exon 19 deletion or Exon 21 L858R). |
| [NCT07012031](https://clinicaltrials.gov/study/NCT07012031) | National Cancer Inst | Trial requires prior treatment with a KRAS G12C inhibitor and immune checkpoint inhibitor, but patient has not received any KRAS G12C inhibitor. |
| [NCT01595074](https://clinicaltrials.gov/study/NCT01595074) | National Cancer Inst | Patient has metastatic NSCLC while trial is focused on early stage NSCLC (Stage IA to IIIB). |
| [NCT02596490](https://clinicaltrials.gov/study/NCT02596490) | M.D. Anderson Cancer | Patient is not currently receiving treatment at MD Anderson Cancer Center as per trial criteria. |
| [NCT03260491](https://clinicaltrials.gov/study/NCT03260491) | Daiichi Sankyo | Trial requires histologically or cytologically documented adenocarcinoma NSCLC, but patient has KRAS G12C mutation without documented histology matching any specified EGFR mutations for Dose Escalation. |
| [NCT03774758](https://clinicaltrials.gov/study/NCT03774758) | University of Califo | Patient is previously treated (docetaxel, ramucirumab) while trial appears to focus on treatment-naive patients. |
| [NCT04712877](https://clinicaltrials.gov/study/NCT04712877) | Lung Cancer Mutation | Patient has metastatic NSCLC while the trial is for clinical stage IA2-III lung cancers. |
| ... | ... | *and 38 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| KRAS G12C | manual | 1.0 |
| KRASG12C | manual | 0.9 |
| KRAS-G12C | manual | 0.9 |
| NSCLC | manual | 1.0 |
| KRAS G12C NSCLC | manual | 1.0 |
| KRAS G12C non-small cell lung cancer | llm | 0.9 |
| KRAS G12C lung adenocarcinoma | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung adenocarcinoma | llm | 0.8 |
| KRAS p.G12C | llm | 0.9 |
| KRASp.G12C | llm | 0.8 |
| KRAS-p.G12C | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Life expectancy estimate** - many trials require â‰¥3 months
- **Cardiac status/QTc interval** - relevant for trials with cardiotoxicity risk
